Scholarlink

Purpose of review <p>The primary objective of this article is to conduct an in-depth exploration of the most recent advancements in incretin-based pharmacological interventions for obesity management, specifically focusing on glucagon-like peptide-1 (GLP-1) and the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. In addition, this article also explores innovative strategies to enhance the effectiveness in abstract of anti-obesity treatments through the integration of individualized guidelines and lifestyle modifications.</p> Recent findings <p>Personalized intensive lifestyle interventions can enhance weight loss and metabolic outcomes and facilitate weight loss maintenance in individuals with overweight/obesity treated with GLP-1 or dual GLP-1/GIP receptor agonists. Providers should discuss side effects, drug-induced weight gain, and coordinate with other specialists during management.</p> Summary <p>Emphasizing a comprehensive, patient-centered clinical algorithm underscores the critical need for a multifaceted approach to achieve effective weight management. This involves a combination of lifestyle interventions and the utilization of incretin-based therapy designed to address the complex and diverse obstacles associated with obesity and maintenance of weight loss.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Optimizing the Efficacy of Anti-Obesity Medications: A Practical Guide to Personalizing Incretin-Based Therapies

  • 期刊论文

  • 发表日期：

    2025年1月15日

查看全文
  • Afua K. Takyi,
  • Robert H. Gaffey,
  • Alpana P. Shukla

摘要

Purpose of review

The primary objective of this article is to conduct an in-depth exploration of the most recent advancements in incretin-based pharmacological interventions for obesity management, specifically focusing on glucagon-like peptide-1 (GLP-1) and the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. In addition, this article also explores innovative strategies to enhance the effectiveness in abstract of anti-obesity treatments through the integration of individualized guidelines and lifestyle modifications.

Recent findings

Personalized intensive lifestyle interventions can enhance weight loss and metabolic outcomes and facilitate weight loss maintenance in individuals with overweight/obesity treated with GLP-1 or dual GLP-1/GIP receptor agonists. Providers should discuss side effects, drug-induced weight gain, and coordinate with other specialists during management.

Summary

Emphasizing a comprehensive, patient-centered clinical algorithm underscores the critical need for a multifaceted approach to achieve effective weight management. This involves a combination of lifestyle interventions and the utilization of incretin-based therapy designed to address the complex and diverse obstacles associated with obesity and maintenance of weight loss.